Stereotaxis: When the Hammer Finds the Nail

Stereotaxis began as a research project--developing a magnetic surgical guidance system--that serendipitously became a company without much regard for commercial prospects. The original design was ahead of the technology curve, but innovations in magnetic and imaging systems fortuitously enabled Stereotaxis to turn this concept into a product. The company's system, however, was and still remains far ahead of the necessary adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue. Looking for applications in other specialties for what it believes is a platform technology, Stereotaxis shifted its focus to cardiology. The company launched a system that has been well-received in the small but growing area of electrophysiology. Most recently, Stereotaxis has begun to focus on what could be its most significant opportunity: interventional cardiology. Here, too, the company appears to be the beneficiary of good timing: in the era of drug-eluting stents, interventionalists are likely to treat more difficult patients, the cases that could benefit most from Stereotaxis' advanced guidance system. The company's system, however, was and still remains far ahead of the adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue.

By Stephen Levin

For medical device companies, sometimes taking the road less traveled in developing new technology can lead to significant opportunities in...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

test carousel

 
• By 

test carousel-In-Vivo

Slow Progress: A Decade Of Cell Therapy In Japan

 
• By 

After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting